Teekachunhatean Supanimit, Kunanusorn Puongtip, Rojanasthien Noppamas, Sananpanich Kanit, Pojchamarnwiputh Suwalee, Lhieochaiphunt Sorasak, Pruksakorn Sumalee
Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Thailand.
BMC Complement Altern Med. 2004 Dec 13;4:19. doi: 10.1186/1472-6882-4-19.
Duhuo Jisheng Wan (DJW) is perhaps the best known and most widely used Chinese herbal recipe for arthralgia, but the clinical study to verify its efficacy is lacking. The purpose of this study was to compare the efficacy of DJW versus diclofenac in symptomatic treatment of osteoarthritis (OA) of the knee.
This study was a randomized, double-blind, double-dummy, controlled trial. The 200 patients suffering from OA of the knee, were randomized into the DJW and diclofenac group. The patients were evaluated after a run-in period of one week (week 0) and then weekly during 4 weeks of treatment. The clinical assessments included visual analog scale (VAS) score that assessed pain and stiffness, Lequesne's functional index, time for climbing up 10 steps, as well as physician's and patients' overall opinions on improvement.
Ninety four patients in each group completed the study. In the first few weeks of treatment, the mean changes in some variables (VAS, which assessed walking pain, standing pain and stiffness, as well as Lequesne's functional index) of the DJW group were significantly lower than those of the diclofenac group. Afterwards, these mean changes became no different throughout the study. Most of the physician's and patients' overall opinions on improvement at each time point did not significantly differ between the two groups. Approximately 30% of patients in both groups experienced mild adverse events.
DJW demonstrates clinically comparable efficacy to diclofenac after 4 weeks of treatment. However, the slow onset of action as well as approximately equal rate of adverse events to diclofenac might limit its alternative role in treatment of OA of the knee.
独活寄生丸(DJW)可能是治疗关节痛最知名且应用最广泛的中药方剂,但缺乏验证其疗效的临床研究。本研究旨在比较独活寄生丸与双氯芬酸对膝关节骨关节炎(OA)进行对症治疗的疗效。
本研究为随机、双盲、双模拟、对照试验。200例膝关节OA患者被随机分为独活寄生丸组和双氯芬酸组。患者在为期1周的导入期(第0周)后进行评估,然后在4周的治疗期间每周评估一次。临床评估包括视觉模拟量表(VAS)评分(评估疼痛和僵硬程度)、Lequesne功能指数、爬10级台阶所需时间,以及医生和患者对改善情况的总体评价。
每组94例患者完成研究。在治疗的最初几周,独活寄生丸组某些变量(评估行走疼痛、站立疼痛和僵硬程度的VAS以及Lequesne功能指数)的平均变化显著低于双氯芬酸组。此后,在整个研究过程中这些平均变化没有差异。在每个时间点,两组医生和患者对改善情况的总体评价大多没有显著差异。两组中约30%的患者经历了轻度不良事件。
治疗4周后,独活寄生丸在临床上显示出与双氯芬酸相当的疗效。然而,起效缓慢以及不良事件发生率与双氯芬酸大致相同,可能会限制其在膝关节OA治疗中的替代作用。